Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 20/20 | 0.78 |
| ▸ | CA12 | O43570 | 16/20 | 0.70 |
| ▸ | CA1 | P00915 | 16/20 | 0.70 |
| ▸ | CA6 | P23280 | 16/20 | 0.70 |
| ▸ | CA5A | P35218 | 16/20 | 0.70 |
| ▸ | CA7 | P43166 | 16/20 | 0.70 |
| ▸ | CA9 | Q16790 | 16/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 16/20 | 0.70 |
| ▸ | CA5B | Q9Y2D0 | 15/20 | 0.70 |
| ▸ | CA4 | P22748 | 15/20 | 0.70 |
| ▸ | CA13 | Q8N1Q1 | 14/20 | 0.70 |
| ▸ | CA3 | P07451 | 13/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18424441 | 0.82 | CA12 (1.00) | CA2CA12CA1CA6CA5A | |
| SCHEMBL18425695 | 0.82 | CA12 (1.00) | CA2CA12CA1CA6CA5A | |
| SCHEMBL29617529 | 0.80 | CA2 (0.70) | CA2CA12CA1CA6CA5A | |
| SCHEMBL18425229 | 0.72 | CA12 (1.00) | CA2CA12CA1CA6CA5A | |
| SCHEMBL18425522 | 0.71 | CA12 (1.00) | CA2CA12CA1CA6CA5A | |
| SCHEMBL18425491 | 0.71 | CA12 (1.00) | CA2CA12CA1CA6CA5A | |
| SCHEMBL18424685 | 0.70 | CA12 (1.00) | CA2CA12CA1CA6CA5A | |
| SCHEMBL24495177 | 0.70 | CA2 (0.67) | CA2CA12CA1CA6CA5A | |
| SCHEMBL29831856 | 0.70 | CA2 (0.67) | CA2CA12CA1CA6CA5A | |
| SCHEMBL18425010 | 0.69 | CA12 (1.00) | CA2CA12CA1CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312682-B2 | Selective inhibitors of carbonic anhydrase | VILNIUS UNIVERSITY (LT) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312682-B2 | Selective inhibitors of carbonic anhydrase | CA2, CA9, CA7 | CA2 1/4885CA12 8/4885CA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.